A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...
The incorporation of all these biomarkers into routine screening could revolutionise prostate cancer management by enabling ...
The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...
Truly game-changing’ prostate cancer test backed by Sir Chris Hoy could help tens of thousands of men - Dr Matthew Hobbs, ...
An emergency physician has pinpointed a trio of "worrying" symptoms that might signal a lethal cancer accountable for nearly ...
Approximately 10–20% of prostate cancer patients develop mCRPC within 5−7 years of diagnosis. 3 Between 1.2–2.1% of all prostate cancer cases globally are mCRPC. 4 The Phase 3 TALAPRO-2 trial is a ...
Oxford BioDynamics announced on Wednesday that it has signed a distribution agreement with Regina Maria, Romania’s largest ...
WYFF News 4's Nigel Robertson has spent more than two decades at WYFF and recently shared his cancer journey after a ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback